The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: A phase II, randomized, double-blind, placebo-controlled, multicenter study

Journal of Clinical Hypertension

Volumn 14, Issue 9, 2012, Pages 580-587

  Andersen, Karl ^a,b   Hartman, Daniel ^c   Peppard, Thomas ^c   Hermann, David ^c   Van Ess, Peter ^c   Lefkowitz, Martin ^d   Trapani, Angelo ^d  

^a Encode Clinic   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c The Great Lakes Drug Development Inc   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6,7 DIHYDRO 5H PYRROLO[1,2 C]IMIDAZOL 5 YL] 3 FLUOROBENZONITRILE PHOSPHATE; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; HYDROCORTISONE; LCI 699; PLACEBO; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREMOR;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; ALDOSTERONE SYNTHASE; ARTERIAL PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 84865760148     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00667.x     Document Type: Article

References (12)

1. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-492.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
3. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
6. Hunt SA, Abraham WT, Chin MH et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults 2009. J Am Coll Cardiol. 2009;53:e1-e90.
7. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442.
8. Zannad F, McMurray JJ, Krum H, et al. for the EMPHASIS-HF group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
9. Chai W, Danser JAH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn-Schmiedeberg's Arch Pharmacol. 2006;374:153-162.
10. Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831-838.
11. Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology, 9th edn. Philadelphia, PA: W.B. Saunders Co; 1988:517.
12. Williams B, Poulter NR, Brown MF et al. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634-640.